… onset, molnupiravir was found to be effective for the treatment of mild to moderate COVID-19…
for outpatients with COVID-19 and at risk of critical illness, molnupiravir is administered …

… severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We here evaluated the
efficacy of molnupiravir in patients with mild-to-moderate coronavirus disease 2019 (COVID-19) …

… In patients with COVID-19, molnupiravir was found to be a safe treatment option that was
well tolerated [46]. In the study by Mazzitelli M et al., 28/407 (6.9%) patients experienced any …

… Our results support the current evidence establishing positive clinical and safety outcomes
of molnupiravir in fully vaccinated patients with mild or moderate breakthrough COVID-19. …

… The efficacy of molnupiravir in treating patients with coronavirus disease 2019 (COVID‐19)
has … the clinical efficacy and safety of molnupiravir for patients with COVID‐19 were included. …

… Given the safety and efficacy of Pfizer/BioNTech mRNA… has received full FDA approval
for COVID-19. Numerous agents … use under EUA for the treatment of mild-moderate SARSCoV-2 …

… with mild or moderate COVID-19. Patients were randomized to orally receive molnupiravir
(… (primary endpoint) was significantly decreased in the molnupiravir group (median, 9 days) …

… The safety, effectiveness, and cost-effectiveness of molnupiravir… admissions in patients with
mild-to-moderate COVID-19. … use of molnupiravir in outpatients with mild-to-moderate COVID-…

… Results: The results of the clinical study in 240 outpatients with mild or moderate COVID-19
showed that molnupiravir at a dose of 800 mg twice daily for 5 days significantly reduced (by …

… safety of molnupiravir in 1433 non-hospitalized adult (18 years or older) participants with …
the agency to grant EUA of molnupiravir in mild to moderate COVID-19 with at least one risk …